Apellis Pharmaceuticals Valuation Multiples

Apellis Pharmaceuticals Overview

About Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Founded

2009

HQ

Employees

739

Website

apellis.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $973M

EBITDA: $25M

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Apellis Pharmaceuticals Financials

Apellis Pharmaceuticals reported last 12-month revenue of $973M and EBITDA of $25M.

In the same LTM period, Apellis Pharmaceuticals generated $869M in gross profit, $25M in EBITDA, and had net loss of ($14M).

Apellis Pharmaceuticals P&L

In the most recent fiscal year, Apellis Pharmaceuticals reported revenue of $1B and EBITDA of $70M.

Apellis Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals has current market cap of $3B, and enterprise value of $3B.

Apellis Pharmaceuticals' stock price is $20.16.

Apellis Pharmaceuticals Valuation Multiples

Apellis Pharmaceuticals trades at 2.7x EV/Revenue multiple, and 104.9x EV/EBITDA.

Apellis Pharmaceuticals Financial Valuation Multiples

As of March 21, 2026, Apellis Pharmaceuticals has market cap of $3B and EV of $3B.

Equity research analysts estimate Apellis Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Apellis Pharmaceuticals has a P/E ratio of (184.6x).

Apellis Pharmaceuticals Margins & Growth Rates

Apellis Pharmaceuticals' revenue in the last 12 month declined by (8%).

Apellis Pharmaceuticals' revenue per employee in the last FY averaged $1.3M.

Apellis Pharmaceuticals' rule of 40 is (5%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Apellis Pharmaceuticals' rule of X is (17%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Apellis Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Apellis Pharmaceuticals M&A Activity

Apellis Pharmaceuticals acquired XXX companies to date.

Last acquisition by Apellis Pharmaceuticals was on XXXXXXXX, XXXXX. Apellis Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Apellis Pharmaceuticals Investment Activity

Apellis Pharmaceuticals invested in XXX companies to date.

Apellis Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Apellis Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).